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have	 a	 worse	 prognosis	 but	 the	 achievement	 of	 a	 pathologic	 complete	 response	 after	 neoadjuvant	
chemotherapy	may	have	good	rates	of	overall	survival.	We	present	the	case	of	a	47	year	old	women	with	
IBC,	luminal	B	and	with	high	proliferative	index;	she	was	successfully	treated	with	a	sequential	schedule	
of	 chemotherapy	 (anthracyclines	 dose-dense/carboplatin+	 taxane/Cyclophosphamide	 Methotrexate	
Fluorouracil),	hormone-therapy,	complementary	radiotherapy	and	 inally	surgery	until	the	achievement	
of	a	complete	clinical	and	pathological	response.





involves	 the	 skin,	 T4c	 involves	 the	 chest	 wall	 and	 the	 skin),	 stages	 IIIC	 (N3	 with	 any	 T)	 and	 the	























































































	 Nowadays,	 primary	 systemic	 treatment	 is	 considered	 the	 standard	 of	 care	 for	 breast	 cancer	
patients	with	locally	advanced	and	in lammatory	breast	cancer.	Stage	III	IBC	is	often	characterized	by	a	
worse	 prognosis	 than	 stage	 III	 non-in lammatory	 tumors,	 with	 increased	 loco-regional	 and	 distant	
recurrence	rates	[9,	10].	 	Although	the	risk	of	contralateral	breast	cancer	following	IBC	is	rare	[8],	our	
patient	presented	a	bilateral	IBC.
	 The	 standard	 treatment	 of	 IBC	 consists	 of	 neo-adjuvant	 chemotherapy	 followed	 by	modi ied	










with	 high	 proliferation	 index	 bene itted	 from	 sequential	 schedules	 of	 chemotherapy	 and	 hormonal	
treatment.	Our	patient	obtained	a	pathological	complete	response	after	less	than	1	year	of	treatment,	
without	affecting	her	quality	of	life,	very	rare	for	a	bilateral	in lammatory	breast	cancer.
	 Our	 patient	 achieved	 an	 excellent	 result	 with	 chemotherapy,	 using	 the	 most	 active	 drugs	
(anthracycline	and	taxane)	but	with	a	peculiar	schedule	that	ensures	a	good	tolerability.	In	fact	the	only	
observed	 toxicities	were	 low,	 the	 only	 severe	 toxicity	was	 alopecia	 G4.	 The	 haematological	 toxicity,	
usually	caused	byanthracycline,	was	avoided	thanks	to	colony	stimulating	factors.
	 Our	patient	responded	very	well	with	a	high	chemosensitivity	to	the	therapy,	therefore	further	
sequential	 chemotherapy	 schemes	were	 performed	 and	 led	 to	 a	 clinical	 and	 instrumental	 pCR.	 The	
subsequent	endocrine-therapy	consolidated	the	results	and	 inally	the	surgery	response	was	excellent.	
Due	 to	 the	 optimal	 response	 after	 antracycline	 and	 taxanes,	 we	 have	 chosen	 to	 treat	 our	 patient	
sequentially	 with	 CMF	 schedule,	 since	 a	 large	 trial	 demonstrated	 ef icacy	 of	 CMF	 for	 IBC,	 with	 an	
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